Home › Trial NCT02926638
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
- Trial IDNCT02926638
- StatusTerminated
- PhasePhase 2/3
- Study typeInterventional
- SponsorSWOG Cancer Research Network
- Enrollment9
- Start date2014-06-16
- ConditionsMET Positive · Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma AJCC v7
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.